Key result
Targeting angiotensinogen with RNA-based therapeutics is a promising strategy for treating hypertension and cardiovascular diseases, potentially requiring only a few administrations per year.
Why the study?
To summarize available data on targeting angiotensinogen with RNA-based therapeutics as a new tool to combat cardiovascular diseases.
Do RNA-based therapeutics targeting angiotensinogen provide effective treatment for hypertension and other cardiovascular diseases?
Do RNA-based therapeutics targeting angiotensinogen provide effective treatment for hypertension and other cardiovascular diseases?
RNA-based therapeutics targeting angiotensinogen represent a promising new strategy for treating hypertension and related diseases with infrequent dosing that could improve patient adherence.
May enhance adherence via infrequent dosing; leaves open validation in prospective randomized trials.
PURPOSE OF REVIEW: To summarize all available data on targeting angiotensinogen with RNA-based therapeutics as a new tool to combat cardiovascular diseases. RECENT FINDINGS: Liver-targeted, stable antisense oligonucleotides and small interfering RNA targeting angiotensinogen are now available, and may allow treatment with at most a few injections per year, thereby improving adherence. Promising results have been obtained in hypertensive animal models, as well as in rodent models of atherosclerosis, polycystic kidney disease and pulmonary fibrosis. The next step will be to evaluate the optimal degree of suppression, synergy with existing renin-angiotensin-aldosterone system blockers, and to determine harmful effects of suppressing angiotensinogen in the context of common comorbidities, such as heart failure and chronic kidney disease. SUMMARY: Targeting angiotensinogen with RNA-based therapeutics is a promising new tool to treat hypertension and diseases beyond. Their long-lasting effects are particularly exciting, and if translated to a clinical application of at most a few administrations per year, may help to eliminate nonadherence.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2019) conducted a review in Cardiovascular diseases and hypertension. RNA-based therapeutics targeting angiotensinogen (antisense oligonucleotides and small interfering RNA) was evaluated. Targeting angiotensinogen with RNA-based therapeutics is a promising strategy for treating hypertension and cardiovascular diseases, potentially requiring only a few administrations per year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: